Trial Profile

A Pilot Phase II Study of a Nucleoside Sparing Regimen of Dolutegravir + Atazanavir/r in HIV-1 Infected Patients With Detectable Viremia (DOLATAV Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atazanavir (Primary) ; Dolutegravir (Primary) ; Ritonavir (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms Dolatav

Most Recent Events

11 Aug 2021 Status changed from recruiting to completed.
24 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
08 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com